Titan Pharmaceuticals, Inc. (OTCMKTS:TTNP)‘s stock had its “buy” rating reiterated by investment analysts at Roth Capital in a note issued to investors on Thursday. They presently have a $6.00 target price on the specialty pharmaceutical company’s stock. Roth Capital’s target price would indicate a potential upside of 224.32% from the stock’s previous close.

Separately, ValuEngine downgraded shares of Titan Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.

Titan Pharmaceuticals (OTCMKTS TTNP) traded up 7.03% on Thursday, hitting $1.98. 111,507 shares of the company were exchanged. Titan Pharmaceuticals has a one year low of $1.30 and a one year high of $6.17. The firm’s market cap is $41.98 million. The stock has a 50 day moving average price of $1.69 and a 200 day moving average price of $2.49.

Titan Pharmaceuticals (OTCMKTS:TTNP) last posted its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.03). The business had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.10 million. Titan Pharmaceuticals had a negative return on equity of 152.57% and a negative net margin of 4,481.82%. On average, equities research analysts forecast that Titan Pharmaceuticals will post ($0.60) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/10/05/titan-pharmaceuticals-inc-ttnp-receives-buy-rating-from-roth-capital.html.

Large investors have recently modified their holdings of the business. LMR Partners LLP bought a new stake in Titan Pharmaceuticals in the second quarter valued at approximately $105,000. Goldman Sachs Group Inc. increased its stake in Titan Pharmaceuticals by 1.6% in the second quarter. Goldman Sachs Group Inc. now owns 102,503 shares of the specialty pharmaceutical company’s stock valued at $195,000 after purchasing an additional 1,570 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan bought a new stake in Titan Pharmaceuticals in the second quarter valued at approximately $576,000.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura.

Receive News & Ratings for Titan Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.